About UDP-sugar transporter protein SLC35A5
UDP-sugar transporter protein SLC35A5 (SLC35A5) is a protein
from Homo sapiens identified by UniProt accession
Q9BS91, 424 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | UDP-sugar transporter protein SLC35A5 |
| UniProt accession | Q9BS91 |
| Gene | SLC35A5 |
| Organism | Homo sapiens |
| Length | 424 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (11)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- eosinophil count · score 0.13
- monoclonal B-cell lymphocytosis · score 0.11
- eosinophil percentage of leukocytes · score 0.03
- drug use measurement · score 0.02
- ovarian carcinoma · score 0.01
- Miyoshi myopathy · score 0.01
- hepatocellular carcinoma · score 0.00
- nervous system disease · score 0.00
- neoplasm · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BS91-F1 | alphafold | PREDICTED | 76.79 | — |
Amino-acid sequence (424 residues)
MEKQCCSHPV ICSLSTMYTF LLGAIFIALS SSRILLVKYS ANEENKYDYL PTTVNVCSEL VKLVFCVLVS FCVIKKDHQS RNLKYASWKE FSDFMKWSIP AFLYFLDNLI VFYVLSYLQP AMAVIFSNFS IITTALLFRI VLKRRLNWIQ WASLLTLFLS IVALTAGTKT LQHNLAGRGF HHDAFFSPSN SCLLFRSECP RKDNCTAKEW TFPEAKWNTT ARVFSHIRLG MGHVLIIVQC FISSMANIYN EKILKEGNQL TESIFIQNSK LYFFGILFNG LTLGLQRSNR DQIKNCGFFY GHSAFSVALI FVTAFQGLSV AFILKFLDNM FHVLMAQVTT VIITTVSVLV FDFRPSLEFF LEAPSVLLSI FIYNASKPQV PEYAPRQERI RDLSGNLWER SSGDGEELER LTKPKSDESD EDTF
Explore UDP-sugar transporter protein SLC35A5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets